Catalyst Wire Dossier Catalyst Wire Dossier

EBGLYSS

LEBRIKIZUMAB-LBKZ · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for EBGLYSS, covering 2024-09-13 to 2026-03-20. Get the full timeline:

Most recent: EMA Authorised: Ebglyss (Lebrikizumab) — Almirall, S.A.

See pricing